Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

addiction

Wargaming in HCV

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of...

Research Partnership

- PMLiVE

Mobile health and patient outcomes

Putting the humanity back into patient care

- PMLiVE

Facing the new wave of biosimilars

Don’t drown out the patient voice, says advocacy group

- PMLiVE

Are healthcare companies delivering great customer experience?

The barriers in improving customer experience in pharma

- PMLiVE

How can pharma better engage and empower patients who are socially disadvantaged?

Knowledge to the people! Power to the people!

- PMLiVE

‘Nothing about us without us’

Why patient engagement is essential throughout the entire product life cycle

- PMLiVE

Just 20% of people living with hep C are aware of their status

WHO's hepatitis report reveals global impact of the disease

Bristol-Myers Squibb (BMS) building

BMS claims a win in mid-stage NASH trial

Its new liver disease therapy reduces fatty deposits and improves blood lipid profiles

- PMLiVE

2016: The year when deal-makers took stock?

Merger-mania and asset swaps slowed and joint ventures were back in fashion

Access and elimination: the future of DAAs in hepatitis C

Published in Pharmaphorum January 2017

Research Partnership

- PMLiVE

J&J partner drive nets 15 new deals, and another NASH drug

Fosters new collaborations in treatment-resistant depression, infectious diseases and cancer

- PMLiVE

GSK targets COPD adherence with integrated inhaler sensors

Hopes real-time patient experience data will improve clinical trial engagement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links